<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03534622</url>
  </required_header>
  <id_info>
    <org_study_id>ML-3341-119</org_study_id>
    <nct_id>NCT03534622</nct_id>
  </id_info>
  <brief_title>Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults</brief_title>
  <official_title>A Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melinta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Melinta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the steady-state intrapulmonary disposition of&#xD;
      delafloxacin in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and pharmacokinetics (PK) of delafloxacin in healthy&#xD;
      adult participants by assessing the intrapulmonary disposition in adults receiving 300 mg&#xD;
      delafloxacin IV every 12 hours for a total of 7 doses over 4 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Actual">July 27, 2018</completion_date>
  <primary_completion_date type="Actual">July 19, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delafloxacin plasma PK:Tmax</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Delafloxacin plasma PK: Cmax</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Delafloxacin plasma PK: AUCτ</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Delafloxacin plasma PK: AUC0-t</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Delafloxacin plasma PK: AUCinf</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Delafloxacin plasma PK: T1/2</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Delafloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing will be initiated on Day 1. All participants will receive 300-mg delafloxacin as a&#xD;
1-hour intravenous infusion every 12 hours (± 15 minutes) for a total of 7 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delafloxacin</intervention_name>
    <description>In this study, thirty subjects who meet the entry criteria will be assigned to 1 of 5 groups (A, B,C, D, or E) to receive 300 mg delafloxacin IV every 12 hours for a total of 7 doses over 4 days</description>
    <arm_group_label>Delafloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has no clinically important abnormal physical findings that could&#xD;
             interfere with the conduct of the study.&#xD;
&#xD;
          -  Participant has no clinically significant laboratory abnormalities.&#xD;
&#xD;
          -  Participant has normal (or abnormal but not clinically significant) ECG measurements.&#xD;
&#xD;
          -  Participant has BMI between 18.0 and ≤30.0 kg/m2, inclusive, or if outside the range,&#xD;
             considered not clinically significant.&#xD;
&#xD;
          -  Participant has normal (or abnormal but not clinically significant) blood pressure and&#xD;
             pulse rate measurements. Blood pressure and pulse rate will be measured after the&#xD;
             participant has been in a sitting position for 5 minutes. For this study, normal blood&#xD;
             pressure is defined as 100 to 140 mmHg systolic and 50 to 90 mmHg diastolic,&#xD;
             inclusive. Normal pulse rate is defined as 50 to 90 beats per minute, inclusive.&#xD;
&#xD;
          -  Participant is willing and able to abstain from alcohol, caffeine, and methylxanthine&#xD;
             containing beverages or food. Alcohol, caffeine, and methylxanthine consumption will&#xD;
             be prohibited within 96 hours before Check-in and throughout the entire study&#xD;
             throughout Follow-up.&#xD;
&#xD;
          -  Participant is able to communicate well with the investigator and comply with the&#xD;
             requirements of the entire study.&#xD;
&#xD;
          -  Participant provides written informed consent to participate as indicated by a&#xD;
             signature on the informed consent form (ICF).&#xD;
&#xD;
          -  Participant agrees to use an adequate method of contraception during the study and for&#xD;
             30 days after the final dose. Female partners of male subjects should also use an&#xD;
             additional reliable method of contraception. Adequate methods of contraception for the&#xD;
             participant and partner include, but are not limited to, condoms with spermicide&#xD;
             gel,diaphragm with spermicide gel, hormonal or nonhormonal intrauterine device,&#xD;
             surgical sterilization, vasectomy, oral contraceptive pill, depot progesterone&#xD;
             injections, or abstinence. If abstinence is indicated as the method of contraception,&#xD;
             the participant must have been abstinent for 6 weeks before enrollment in the study.&#xD;
             If a participant is usually not sexually active but becomes active, the participant&#xD;
             and his or her partner should use one of the listed contraceptive methods.&#xD;
&#xD;
          -  Female subjects of childbearing potential must be nonpregnant, nonlactating, and have&#xD;
             a negative serum human chorionic gonadotropin pregnancy test at Screening and a&#xD;
             negative urine pregnancy test at Check-In.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has received any investigational drug within 30 days before administration&#xD;
             of the first dose of the study drug (6 months for biologic therapies) or 5 half-lives&#xD;
             of the investigational drug, if known, whichever time period is longer.&#xD;
&#xD;
          -  Participant has received delafloxacin previously.&#xD;
&#xD;
          -  Participant is a female who is pregnant or breastfeeding. Pregnancy status will be&#xD;
             confirmed by serum assay for qualitative human chorionic gonadotropin at Screening and&#xD;
             a urine assay performed at Check-in.&#xD;
&#xD;
          -  Participant has a positive test result for alcohol, amphetamines, barbiturates,&#xD;
             benzodiazepines, cocaine metabolites, opiates, cannabinoids, or cotinine, at Screening&#xD;
             or Check-in.&#xD;
&#xD;
          -  Participant has a positive screening test for hepatitis B surface antigen, hepatitis C&#xD;
             antibody, and/or human immunodeficiency virus antibodies.&#xD;
&#xD;
          -  Participant has any surgical or medical condition that, in the judgment of the&#xD;
             investigator,might interfere with the absorption, distribution, metabolism, or&#xD;
             excretion of the study drug.&#xD;
&#xD;
          -  Participant has used any medication (prescription or over-the-counter [OTC], including&#xD;
             health supplements and herbal remedies, with the exception of acetaminophen (as&#xD;
             described in Exclusion Criterion 9) within 2 weeks (4 weeks for enzyme inducers&#xD;
             including St John's wort [Hypericum perforatum]) or 5 half-lives (whichever is longer)&#xD;
             before the first dose of study drug.&#xD;
&#xD;
          -  Participant has used an oral or IV antibiotic within 3 months of administration of the&#xD;
             first dose of the study drug.&#xD;
&#xD;
          -  Participant has routinely or chronically used more than 1 g of acetaminophen daily.&#xD;
&#xD;
          -  Participant has performed strenuous activity, sunbathing, and/or contact sports within&#xD;
             96 hours (4 days) before Check-in on Day -1. The participant should abstain from these&#xD;
             activities for the duration of the study.&#xD;
&#xD;
          -  Participant has donated or lost greater than 400 mL of blood in the 30 days before&#xD;
             administration of the first dose of study drug.&#xD;
&#xD;
          -  Participant is unable to be venipunctured or tolerate venous access as determined by&#xD;
             the investigator or designee.&#xD;
&#xD;
          -  Participant has a history of any significant drug allergy (such as anaphylaxis or&#xD;
             hepatotoxicity) or drug reaction (angioedema, atopic dermatitis, or uticaria),&#xD;
             including medical history of significant hypersensitivity or allergic reaction to&#xD;
             quinolones or beta-lactam antibiotics, lidocaine, or similar compounds. Participants&#xD;
             with a history of seasonal allergies are allowed unless the allergy is active or has&#xD;
             required treatment within the past 30 days.&#xD;
&#xD;
          -  Participant has a history of clinically significant, clinically relevant hematologic,&#xD;
             renal, hepatic, bronchopulmonary (including history of chronic respiratory disorders,&#xD;
             anatomy not conducive for bronchoscopy), neurological, psychiatric, metabolic,&#xD;
             endocrine disorder (eg, diabetes, thyroid disease) or cardiovascular disease, in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
          -  Subject has a history of clinically significant GI disease, or gastroenteritis&#xD;
             (vomiting or diarrhea) or any history of GI bleeding (excluding bleeding from&#xD;
             hemorrhoids), and/or surgery that would result in the subject's inability to absorb or&#xD;
             metabolize the study drug (eg, gastrectomy, gastric bypass, cholecystectomy).&#xD;
&#xD;
          -  Participant has a history of any drug or alcohol abuse in the past 2 years, or alcohol&#xD;
             consumption greater than 21 units per week in males and 14 units per week in females.&#xD;
             A unit of alcohol is equivalent to 1 can of beer, 1 glass of wine, or the equivalent&#xD;
             of 1 alcoholic drink. Alcohol consumption will be prohibited within 96 hours before&#xD;
             Check-in on Day -1 and throughout the entire study until Follow-up.&#xD;
&#xD;
          -  Participant currently smokes or has smoked in the past year or uses or has used&#xD;
             nicotine or nicotine containing products in the past 6 months.&#xD;
&#xD;
          -  Participant has had any major surgery within 4 weeks of study drug administration.&#xD;
&#xD;
          -  Participant has a history of malignancy within the past 5 years other than past&#xD;
             history of localized or surgical removal of focal basal cell skin cancer, cervical&#xD;
             cancer in situ treated successfully in the past by local treatment (including but not&#xD;
             limited to cryotherapy or laser therapy), or by hysterectomy.&#xD;
&#xD;
          -  Participant has any clinically significant concomitant disease or condition that could&#xD;
             interfere with, or for which the treatment might interfere with, the conduct of the&#xD;
             study, or that would, in the opinion of the investigator, pose an unacceptable risk to&#xD;
             the participants in the study.&#xD;
&#xD;
          -  Participation in another clinical study within 30 days of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue K Cammarata, MD</last_name>
    <role>Study Director</role>
    <affiliation>CMO, MelintaTherapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <last_update_submitted>August 14, 2018</last_update_submitted>
  <last_update_submitted_qc>August 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

